1024 related articles for article (PubMed ID: 21497433)
21. [Benign prostate hyperplasia with chronic prostatitis: an update].
Ma Y; Zhang WL
Zhonghua Nan Ke Xue; 2010 Jul; 16(7):646-50. PubMed ID: 20873602
[TBL] [Abstract][Full Text] [Related]
22. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
23. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
Gerstenbluth RE; Seftel AD; MacLennan GT; Rao RN; Corty EW; Ferguson K; Resnick MI
J Urol; 2002 May; 167(5):2267-70. PubMed ID: 11956490
[TBL] [Abstract][Full Text] [Related]
24. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
25. [Role of apoptosis and chronic prostatitis in the pathogenesis of benign prostatic hyperplasia].
Pawlicki B; Zieliński H; Dabrowski M
Pol Merkur Lekarski; 2004 Oct; 17(100):307-10. PubMed ID: 15690689
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
27. The role of inflammation and infection in the pathogenesis of prostate carcinoma.
Wagenlehner FM; Elkahwaji JE; Algaba F; Bjerklund-Johansen T; Naber KG; Hartung R; Weidner W
BJU Int; 2007 Oct; 100(4):733-7. PubMed ID: 17662075
[TBL] [Abstract][Full Text] [Related]
28. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
[TBL] [Abstract][Full Text] [Related]
29. Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis.
Tsujimoto Y; Takayama H; Nonomura N; Okuyama A; Aozasa K
Prostate; 2002 Sep; 52(4):279-87. PubMed ID: 12210488
[TBL] [Abstract][Full Text] [Related]
30. Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.
Tokmadžić VS; Tomaš MI; Sotošek S; Laškarin G; Dominović M; Tulić V; Dorđević G; Sustić A; Mrakovčić-Šutić I
Scand J Immunol; 2011 Oct; 74(4):368-76. PubMed ID: 21535078
[TBL] [Abstract][Full Text] [Related]
31. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases.
Brössner C; Petritsch K; Fink K; Auprich M; Madersbacher S; Adlercreutz H; Rehak P; Petritsch P
Urology; 2004 Oct; 64(4):707-11. PubMed ID: 15491706
[TBL] [Abstract][Full Text] [Related]
32. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
33. [Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer].
Zhang F; Si-Mu-Jiang-Abula A; Zhang LD
Zhonghua Nan Ke Xue; 2014 Apr; 20(4):354-8. PubMed ID: 24873164
[TBL] [Abstract][Full Text] [Related]
34. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
35. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
36. [Predictive value of the asymptomatic prostatic inflammation in the development of prostate cancer].
Molimard B; Camparo P; Desfemmes FR; Durand X; Haus R; Deligne E; Houlgatte A; Compérat E
Prog Urol; 2010 Jul; 20(7):508-14. PubMed ID: 20656273
[TBL] [Abstract][Full Text] [Related]
37. Inflammation and prostate cancer.
Sugar LM
Can J Urol; 2006 Feb; 13 Suppl 1():46-7. PubMed ID: 16526982
[TBL] [Abstract][Full Text] [Related]
38. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
39. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
40. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.
Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
